PYY and impulse control disorder: Notably, upon secretion, PYY1–36 is swiftly cleaved by the intestinal serine protease DPP-IV into the active form PYY3–36, undergoing evaluation in various clinical trials as a potential weight-loss drug.12 This study also confirms the therapeutic potential of PYY in the treatment of inflammatory intestinal diseases, such as ileal Crohn’s disease (iCD), where the impaired function of Paneth cells and reduced PYY release coincide with increased pathogenic hyphae in the gut.